Form 4: BioLargo Director Linda Park Receives Stock Options

BioLargo, Inc. Director Linda Park was granted 101,736 stock options as compensation for board services, exercisable at $0.1843 per share.

Summary

• Linda Park, a Director of BioLargo, Inc. (BLGO), acquired 101,736 derivative securities in the form of an option to purchase common stock.
• The option has an exercise price of $0.1843 per share.
• The transaction date for the option grant was December 31, 2025, and it becomes exercisable on the same date.
• The option is set to expire on December 31, 2035.
• This option was issued as payment for $18,750 in fees due to Ms. Park for her services on the board of directors for the most recently completed quarterly period.
• The grant was made pursuant to BioLargo's 2024 Equity Incentive Plan.
• Following this transaction, Ms. Park beneficially owns 1,265,761 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director as compensation is a routine and generally positive event, as it aligns the director's interests with shareholder value creation, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The use of an equity incentive plan demonstrates a structured approach to executive and director compensation.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the expiration date of the granted options.

Management Comments

• The option was issued to Reporting Person as payment for $18,750 in fees due for services on the board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

Industry Context

This transaction represents a routine insider compensation event, common across industries for public company directors, where equity is used to align leadership interests with long-term company performance.

Comparison to Industry Standards

• The practice of compensating directors with stock options is a widely accepted industry standard, aligning director incentives with shareholder value, similar to practices at companies across various sectors.
• The use of a formal Equity Incentive Plan (BioLargo's 2024 plan) for such grants is also standard corporate governance, ensuring transparency and adherence to pre-approved compensation structures.

Corporate Governance

Related Party Transactions

• The issuance of stock options to Director Linda Park as compensation for board services constitutes a related party transaction, which is a standard practice for director remuneration.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from aligned director incentives for long-term company performance.
• Employees: No direct impact mentioned in this filing.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to a director as compensation for board services. While it aligns director interests with shareholders, it does not present new information that would warrant a change in investment recommendation based solely on this disclosure.

Keywords

BioLargo, BLGO, Stock Options, Director Compensation, Equity Incentive Plan, SEC Form 4, Insider Transaction